Literature DB >> 19843934

A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments.

Akio Ohta1, Akiko Ohta, Manasa Madasu, Radhika Kini, Meenakshi Subramanian, Nipun Goel, Michail Sitkovsky.   

Abstract

Immunosuppressive signaling via the A2A adenosine receptor (A2AR) provokes a mechanism that protects inflamed tissues from excessive damage by immune cells. This mechanism is desirable not only for preventing uncontrolled tissue destruction by overactive immune responses, but also for protecting tumor tissues from antitumor immune responses. In aforementioned circumstances, T cell priming may occur in an environment containing high concentrations of extracellular adenosine. To examine qualitative changes in T cells activated in the presence of adenosine, we asked whether different functional responses of T cells are equally susceptible to A2AR agonists. In this study, we demonstrate that A2AR signaling during T cell activation strongly inhibited development of cytotoxicity and cytokine-producing activity in T cells, whereas the inhibition of T cell proliferation was only marginal. Both CD8(+) and CD4(+) T cells proliferated well in the presence of A2AR agonists, but their IFN-gamma-producing activities were susceptible to inhibition by cAMP-elevating A2AR. Importantly, the impaired effector functions were maintained in T cells even after removal of the A2AR agonist, reflecting T cell memory of the immunoregulatory effect of adenosine. Thus, although the adenosine-rich environment may allow for the expansion of T cells, the functional activation of T cells may be critically impaired. This physiological mechanism could explain the inefficiency of antitumor T cells in the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843934     DOI: 10.4049/jimmunol.0901247

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  76 in total

Review 1.  Modifying radiation damage.

Authors:  Kwanghee Kim; William H McBride
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

Review 2.  Regulation of lymphocyte function by adenosine.

Authors:  Joel Linden; Caglar Cekic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-07-05       Impact factor: 8.311

3.  Radiation enhances regulatory T cell representation.

Authors:  Evelyn L Kachikwu; Keisuke S Iwamoto; Yu-Pei Liao; John J DeMarco; Nzhde Agazaryan; James S Economou; William H McBride; Dörthe Schaue
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-17       Impact factor: 7.038

4.  Adenosine 2A receptor promotes collagen production by human fibroblasts via pathways involving cyclic AMP and AKT but independent of Smad2/3.

Authors:  Miguel Perez-Aso; Patricia Fernandez; Aránzazu Mediero; Edwin S Chan; Bruce N Cronstein
Journal:  FASEB J       Date:  2013-11-07       Impact factor: 5.191

Review 5.  Adenosine-mediated immunosuppression in patients with squamous cell carcinoma of the head and neck.

Authors:  M Mandapathil
Journal:  HNO       Date:  2016-05       Impact factor: 1.284

6.  Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes.

Authors:  David M Woods; Andressa S Laino; Aidan Winters; Jason Alexandre; Daniel Freeman; Vinay Rao; Santi S Adavani; Jeffery S Weber; Pratip K Chattopadhyay
Journal:  JCI Insight       Date:  2020-06-04

7.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales.

Authors:  Gregory T Motz; George Coukos
Journal:  Nat Rev Immunol       Date:  2011-09-23       Impact factor: 53.106

Review 8.  Adenosine signaling and adenosine deaminase regulation of immune responses: impact on the immunopathogenesis of HIV infection.

Authors:  Daniela F Passos; Viviane M Bernardes; Jean L G da Silva; Maria R C Schetinger; Daniela Bitencourt Rosa Leal
Journal:  Purinergic Signal       Date:  2018-08-10       Impact factor: 3.765

Review 9.  Adenosinergic signaling as a target for natural killer cell immunotherapy.

Authors:  Jiao Wang; Sandro Matosevic
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

10.  Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors:  Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal:  Trends Cancer       Date:  2016-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.